Ascentage Reports First Patient Dosing of Lisaftoclax (APG-2575) in P-II (APG2575CC201) Study for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Shots:
- The first patient has been dosed in the P-II (APG2575CC201) study to evaluate lisaftoclax in patients with r/r CLL/SLL in China
- The 1EPs of the study is ORR & the patients experienced rapid disease progression and respond poorly to salvage treatments. The results can be used to support the NDA for the treatment of r/r CLL/SLL, based on existing safety and efficacy data
- Lisaftoclax is Bcl-2 selective inhibitor & is designed to selectively block the antiapoptotic protein Bcl-2 to restore the normal apoptosis process in cancer cells. The therapy is being evaluated in multiple studies in countries & regions including the US, China, Australia & EU for solid tumors and hematologic malignancies
Ref: PR Newswire | Image: Ascentage Pharma
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
